United KingdomA UK-based medical trial conducted by King's College London and published in Nature Medicine found that psilocybin, the active compound in magic mushrooms, showed promise in treating treatment-resistant depression. Of 60 participants with depression unresponsive to previous treatments, over 40% experienced symptom remission within three weeks after receiving 25mg of psilocybin. This rate increased to 56% by six weeks, compared to just 3% in the placebo group. The study, funded by public resources, highlighted both the potential therapeutic benefits and the emotionally intense experiences reported by participants. Researchers emphasized the need for further research and noted the growing body of evidence supporting psilocybin therapy.
Bias read (Center): The article presents the findings of a scientific study without overt ideological framing. While the topic relates to mental health treatment and drug policy, which can have political implications, the tone remains neutral, focusing on empirical data and expert opinions rather than advocacy or polem
